Alex Zacharek Selected Research

Chemokine CCL2 (Monocyte Chemoattractant Protein 1)

1/2022	Post-Stroke Administration of L-4F Promotes Neurovascular and White Matter Remodeling in Type-2 Diabetic Stroke Mice.
6/2018	APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats.
1/2017	MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke.
1/2016	MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alex Zacharek Research Topics

Disease

49	Stroke (Strokes) 01/2022 - 03/2005
19	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2020 - 08/2006
7	Cognitive Dysfunction 01/2022 - 01/2019
7	Neoplasms (Cancer) 01/2008 - 09/2002
4	Neuroinflammatory Diseases 01/2022 - 01/2016
4	Fibrosis (Cirrhosis) 01/2021 - 01/2018
4	Infarction (Infarctions) 12/2018 - 01/2013
4	Carcinoma (Carcinomatosis) 01/2008 - 01/2003
4	Neoplasm Metastasis (Metastasis) 07/2006 - 09/2002
3	Body Weight (Weight, Body) 01/2022 - 01/2021
3	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2022 - 01/2019
3	Cardiomegaly (Heart Hypertrophy) 01/2021 - 01/2020
3	Hypertrophy 01/2020 - 01/2017
3	Inflammation (Inflammations) 12/2019 - 01/2013
3	Diabetes Mellitus 06/2018 - 02/2011
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 11/2016 - 01/2013
2	Weight Loss (Weight Reduction) 01/2022 - 12/2020
2	Ischemic Stroke 01/2021 - 03/2015
2	Type 2 Diabetes Mellitus (MODY) 09/2015 - 07/2011
2	Arteriosclerosis 01/2013 - 12/2011
2	Prostatic Neoplasms (Prostate Cancer) 07/2006 - 02/2004
2	Melanoma (Melanoma, Malignant) 08/2004 - 09/2002
1	Hemorrhage 01/2022
1	Memory Disorders (Memory Loss) 06/2021
1	Ischemia 01/2021
1	Cerebral Hemorrhage 10/2019
1	Hyperlipidemias (Hyperlipidemia) 10/2019
1	Chronic Subdural Hematoma 10/2019
1	Hematoma 10/2019

Drug/Important Bio-Agent (IBA)

8	Phosphates (Orthophosphate)IBA 01/2021 - 11/2007
8	Proteins (Proteins, Gene)FDA Link 08/2019 - 08/2004
7	Angiopoietin-1IBA 01/2022 - 01/2009
6	Neuroprotective AgentsIBA 01/2022 - 01/2013
6	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2018
6	Peptides (Polypeptides)IBA 01/2022 - 01/2016
6	Therapeutic UsesIBA 01/2019 - 10/2009
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2018 - 03/2005
5	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2013 - 03/2005
4	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2022 - 01/2016
4	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 06/2021 - 03/2005
4	Liver X ReceptorsIBA 01/2017 - 01/2010
4	SilverIBA 10/2014 - 09/2010
4	SynaptophysinIBA 01/2013 - 09/2010
4	Simvastatin (Zocor)FDA LinkGeneric 01/2012 - 01/2009
4	Niacin (Nicotinic Acid)FDA LinkGeneric 10/2010 - 07/2007
4	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)IBA 07/2006 - 01/2003
3	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2019
3	Blood Glucose (Blood Sugar)IBA 01/2021 - 11/2016
3	Apolipoproteins E (ApoE)IBA 06/2020 - 01/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2019 - 10/2010
3	Oxygen (Dioxygen)IBA 01/2019 - 02/2011
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 02/2011
3	HDL LipoproteinsIBA 01/2016 - 10/2010
3	Nitric Oxide DonorsIBA 01/2009 - 08/2006
3	2,2'- (hydroxynitrosohydrazono)bis- ethanamineIBA 01/2009 - 08/2006
2	Insulin-Like PeptidesIBA 01/2022 - 12/2016
2	Amyloid beta-PeptidesIBA 06/2021 - 08/2019
2	Thrombin FDA Link 01/2021 - 08/2019
2	VasculotideIBA 01/2021 - 12/2018
2	LipidsIBA 12/2020 - 01/2003
2	Apolipoprotein E2IBA 06/2020 - 10/2018
2	CytokinesIBA 01/2020 - 10/2019
2	Atorvastatin (Lipitor)FDA Link 10/2019 - 01/2008
2	Amyloid (Amyloid Fibrils)IBA 08/2019 - 02/2011
2	CholesterolIBA 10/2018 - 01/2016
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 06/2018 - 01/2013
2	GW 3965IBA 01/2017 - 01/2013
2	Luxol Fast Blue MBS (Luxol fast blue)IBA 10/2014 - 02/2011
2	HDL CholesterolIBA 01/2013 - 10/2010
2	OccludinIBA 01/2013 - 08/2006
2	Streptozocin (Streptozotocin)FDA Link 01/2013 - 12/2011
2	angiogeninIBA 01/2013 - 12/2011
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 12/2011 - 07/2007
2	AngiopoietinsIBA 07/2011 - 08/2006
2	ChemokinesIBA 10/2009 - 01/2007
2	ThromboxanesIBA 01/2008 - 02/2004
2	Arachidonic Acid (Vitamin F)IBA 07/2006 - 01/2003
2	AcidsIBA 07/2006 - 01/2003
2	EnzymesIBA 08/2004 - 02/2004
1	Toll-Like Receptor 4IBA 01/2022
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2022
1	Apoprotein(a) (Apolipoprotein (a))IBA 01/2022
1	AlbuminsIBA 01/2022
1	Aquaporin 4IBA 06/2021
1	Interleukin-1 Receptor-Associated KinasesIBA 06/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2021
1	UbiquitinIBA 01/2021
1	NADPH Oxidase 2IBA 01/2021
1	NADP (NADPH)IBA 01/2021
1	Pregnenolone Carbonitrile (PCN)IBA 01/2021
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 01/2021
1	Aquaporins (Water Channels)IBA 12/2019
1	Liposomes (Liposome)IBA 10/2019
1	InterleukinsIBA 10/2019
1	Pharmaceutical PreparationsIBA 10/2019
1	Tissue Plasminogen Activator (Alteplase)FDA Link 08/2019
1	FibrinIBA 08/2019

Therapy/Procedure

6	Therapeutics 09/2015 - 01/2007
2	Splenectomy 01/2020 - 01/2020